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Bioengineering Research Partnerships
Participating Institutes and Centers (ICs) of
the National Institutes of Health (NIH)
invite applications for R01 awards to support
Bioengineering Research Partnerships (BRPs)
for basic, applied, and translational multi-dis-
ciplinary research that addresses important
biological or medical research problems. In
the context of this program, a partnership is a
multi-disciplinary research team that applies
an integrative, systems approach to develop
knowledge and/or methods to prevent,
detect, diagnose, or treat disease or to under-
stand health and behavior. The partnership
must include appropriate bioengineering or
allied quantitative sciences in combination
with biomedical and/or clinical components.
The Principal Investigator (PI) also serves as
the project manager and must be capable of
leading the proposed effort. A BRP may pro-
pose design-directed, developmental, discov-
ery-driven, or hypothesis-driven research at
universities, national laboratories, medical
schools, large or small businesses, or other
public and private entities or combinations of
these entities. It is expected that a BRP will
have a well-defined goal or deliverable that
will be achieved based on objective mile-
stones speciﬁed in the initial application. On
11 October 2001, the NIH issued a related
program announcement (PA) PA-02-011
(http://grants.nih.gov/grants/guide/pa-
files/PA-02-011.html) for Bioengineering
Research Grants (BRGs). The BRGs differ
from the BRPs in that the research will be
performed in a single laboratory, by a single 
investigator, or by a small group of investiga-
tors. On 16 January 2003, the NIH issued
another related PA (PA-03-058), (http://
grants.nih.gov/grants/guide/pa-files/PA-03-
058.html) for Exploratory/Developmental
(R21) Bioengineering Research Grants
(EBRG).  The EBRGs differ from the BRPs
in that (1) the research will be performed in a
single laboratory, by a single investigator, or
by a small group of investigators and (2) the
projects are high-risk/high-payoff in nature
(R21 mechanism) as compared to the R01-
type grants supported by the BRP program. 
Many of today’s biomedical problems are
best addressed using a multi-disciplinary
approach that extends beyond the traditional
biological and clinical sciences. Bioengineering
integrates principles from a diversity of techni-
cal and biomedical fields and crosses the
boundaries of many scientiﬁc disciplines repre-
sented throughout academia, laboratories, and
industry. The creativity of interdisciplinary
teams is resulting in new basic understandings,
novel products, and innovative technologies
for addressing biomedical problems.
Recognizing the importance of bioengineering
in public health, the Bioengineering
Consortium (BECON) was established in
1997 as a focus for bioengineering activities at
the NIH. To facilitate communication
between the allied and biomedical disciplines
and to provide input from the scientiﬁc com-
munity on research needs and directions, the
BECON has held annual two-day symposia
on emerging topics of interest related to bio-
engineering including bioengineering (1998),
bioimaging (1999), nanotechnology (2000),
reparative medicine (2001), biosensors (2002),
and team science (2003).  Summaries of the
proceedings and recommendations of these
symposia are available on the internet at http://
www.becon.nih.gov/becon_symposia.htm. 
Discussions and recommendations of
symposia participants aided in the formula-
tion of the BRP, BRG, and EBRG PAs. It is
expected that some applications submitted in
response to the BRP, BRG, and EBRG PAs
will focus on technology development rather
than on proving or disproving scientific
hypotheses. In support of this approach, NIH
instructions to applicants and review criteria
emphasize that a project may “…test a stated
hypothesis, create a novel design, solve a spe-
cific problem, or develop new technology”
(PHS 398 instructions for the research plan).
The primary objective of this PA is to
encourage basic, applied, and translational
bioengineering research that could make a
signiﬁcant contribution to improving human
health. Bioengineering integrates physical,
engineering, and computational science prin-
ciples for the study of biology, medicine,
behavior, or health. It advances fundamental
concepts, creates knowledge from the molec-
ular to the organ systems level, and develops
innovative biologicals, materials, processes,
implants, devices, and informatics approaches
for the prevention, diagnosis, and treatment
of disease, for patient rehabilitation, and for
improving health. Some BRP projects may
propose research that could lead to a novel
device as a product. Partnership with compa-
nies that have relevant expertise or that may
eventually be involved in commercialization
is appropriate under the BRP program.
A second objective is to encourage collabo-
rations and partnerships among the allied quan-
titative and biomedical disciplines. A BRP must
bring together the necessary physical, engineer-
ing, and computational science expertise with
biological or clinical expertise and resources to
address a significant area of bioengineering
research within the mission of the NIH. In
addition to the beneﬁts to be derived from the
research, the collaborations and partnerships
can create opportunities for trans-disciplinary
communication and training for a new genera-
tion of scientists capable of interacting across
traditional technical boundaries. Applications
for a BRP award should focus on an area of
basic, applied, translational, behavioral, or clini-
cal research in bioengineering that supports the
missions of the participating NIH institutes and
centers and where progress is likely to make a
signiﬁcant contribution to improving human
health. Some NIH institutes and centers have
indicated that they will only consider BRP
applications in speciﬁc focus areas. These insti-
tutes and focus areas are available at http://
www.becon.nih.gov/becon_brpareas.htm.
This PA uses the NIH R01 award mecha-
nism. As an applicant, you are solely responsible
for planning, directing, and executing the pro-
posed project. This PA uses just-in-time con-
cepts. It also uses the modular budgeting as well
as the non-modular budgeting formats (see
http://grants.nih.gov/grants/funding/modu-
lar/modular.htm). Speciﬁcally, if you are sub-
mitting an application with direct costs in each
year of $250,000 or less, use the modular bud-
get format. Otherwise follow the instructions
for non-modular budget research grant applica-
tions. This program does not require cost shar-
ing as deﬁned in the current NIH Grants Policy
Statement at http://grants.nih.gov/grants/pol-
icy/nihgps_2001/part_i_1.htm. 
The initial period of support of a BRP
award may be up to five years. The award
may be competitively renewed for a total of
up to ten years of NIH funding. Competing
renewal and revised applications for BRP
grants are to be received at the NIH on the
same receipt dates as new BRP applications.
For new grants, the maximum total
(direct plus facilities and administrative
[F&A] costs) budget to be awarded in any
year is $2 million. The number of awards
and level of support will depend on the num-
ber of applications of high scientific merit
that are received and the availability of funds.
Funding in subsequent years will be contin-
gent upon satisfactory progress during the
preceding year(s) and the availability of
funds. Applicants are strongly encouraged to
discuss budget requests with NIH scientific
and financial contacts listed under WHERE
TO SEND INQUIRIES prior to submission.
Grantees have the authority to extend the
duration of a BRP grant on a no-cost basis.
This extension provides additional time to
use funds that remain available at the end of
the project period to continue pursuing the
aims of the grant. Grantees should notify the
Grants Management Ofﬁcer of the awarding
institute or center of the no-cost extension as
early as possible and before the expiration of
the grant.
Research Focus Areas: Applicants are
strongly advised to contact IC scientiﬁc pro-
gram staff listed under WHERE TO SEND
INQUIRIES to discuss the relevance of their
proposed work to the institute's mission before
preparing a detailed research application.
Detailed information on research missions and
programs for each NIH institute and center is
available on the participating ICs Web sites,
which are listed at the beginning of this PA.
Some NIH institutes and centers have indi-
cated that they may only want to consider BRP
applications in speciﬁc focus areas. As they are
available, these institutes and focus areas will
be posted at http://www.becon.nih.gov/
becon_brpareas.htm. 
Letter of Intent: Prospective applicants
are asked to submit a letter of intent that
includes the following information: Number
and title of this PA; Descriptive title of the
proposed research; Name, address, telephone
number, and e-mail address of the Principal
Investigator; List of participating institutions
and key personnel. Although a letter of intent
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is not required, is not binding, and does not
enter into the review of a subsequent applica-
tion, the information that it contains allows
NIH staff to estimate the potential review
workload, plan the review, and evaluate pro-
grammatic impacts of the proposals. The let-
ter of intent should be sent to: Dr. Richard
E. Swaja, National Institute of Biomedical
Imaging and Bioengineering (NIBIB), 6707
Democracy Boulevard, Suite 200, Bethesda,
MD 20892-5469 USA, 301-451-4779 fax:
301-480-4973, email: swajar@nibib.nih.gov
BRP Organizational Structure,
Leadership, and Management: An organiza-
tional structure that clearly defines the part-
nership and relationships among the various
components must be developed and
described in the application. The BRP size,
structure, and mode of operation should
match the needs and scope of the proposed
research. NIH policy requires that a single PI
be designated on the face page of all applica-
tions. While this individual is responsible for
the scientiﬁc and technical aspects, as well as
the proper conduct of the project, the struc-
ture of the BRP may involve more than one
individual in developing the application and
in making decisions concerning planning,
management, staffing, and resource alloca-
tion. In recognition of the essential intellec-
tual and/or technical contributions of the
lead scientists responsible for developing and
implementing the goals of the proposal, the
BRP organizational structure must include a
“Leadership Statement” that specifies the
roles of the individuals that provide major
intellectual and/or technical contributions.
The PI has the responsibility and authority to
use BRP funds in the most productive way to
achieve the goals defined at the time of the
award. To accomplish these tasks, the PI in
collaboration with other individuals identi-
ﬁed in the “Leadership Statement” can adjust
funding among BRP participants to support
new partners or to reduce support to existing
partners as needed. The BRP should establish
a Scientific Steering Group that consists of
representatives from each of the partnering
organizations and meets regularly to discuss
project status, problems, and directions.
Those individuals identified in the
“Leadership Statement,” who together would
have the intellectual and leadership responsi-
bilities normally attributed to the PI, would
likely be members of the Scientific Steering
Group.
BRP PI Meeting: BRP PIs will meet
annually in Bethesda, Maryland, to share
results, to ensure that the NIH has a coherent
view of the advances in these fields, and to
have an opportunity for collective problem
solving among the PIs. The cost of participat-
ing in this annual meeting should be
included in the BRP budget.
Applications must be prepared using the
PHS 398 research grant application instruc-
tions and forms (rev. 5/2001). Applications
must have a Dun and Bradstreet (D&B)
Data Universal Numbering System (DUNS)
number as the Universal Identifier when
applying for Federal grants or cooperative
agreements. The DUNS number can be
obtained by calling 866-705-5711 or through
the web site at http://www.dunandbrad-
street.com/. The DUNS number should be
entered on line 11 of the face page of the
PHS 398 form. The PHS 398 is available at
http://grants.nih.gov/grants/funding/phs398/
phs398.html in an interactive format. For
further assistance contact GrantsInfo, 301-
435-0714, e-mail: GrantsInfo@nih.gov.
Application Receipt Dates: New and
competing renewal applications submitted in
response to this PA will be accepted on
January 21, 2004; August 20, 2004; January
20, 2005; August 19, 2005; January 20,
2006; and August 22, 2006. These are the
dates that applications must be received at
the NIH. 
Applications must be received on or
before the receipt dates described as listed on
the first page of this PA. The CSR will not
accept any application in response to this PA
that is essentially the same as one currently
pending initial review unless the applicant
withdraws the pending application. The CSR
will not accept any application that is essen-
tially the same as one already reviewed. This
does not preclude the submission of a sub-
stantial revision of an unfunded version of an
application already reviewed, but such appli-
cation must include an Introduction address-
ing the previous critique. 
Contact: Dr. Richard E. Swaja, NIBIB,
6707 Democracy Boulevard, Suite 200,
Bethesda, MD 20892-5469 USA, 301-451-
4779, fax: 301-480-4973, e-mail:
swajar@nibib.nih.gov; Dr. Eileen Bradley,
Center for Scientific Review, NIH, 6701
Rockledge Drive, Bethesda, MD 20892-
0001, 301-435-1179, fax: 301-480-2241,
e-mail: bradleye@csr.nih.gov
Circulating Cells in Cancer Detection
The purpose of this PA is to develop novel
technologies for capturing, enriching, and
preserving exfoliated abnormal cells and
macromolecules in body fluids or effusions
and to develop methods for concentrating the
enriched cells for biomarker studies. In the
context of this PA, we have extended the deﬁ-
nition of exfoliation to include not only the
cellular materials, but also subcellular materi-
als, such as DNA and proteins. In body ﬂuids,
such as sputum, the number of exfoliated
tumor cells is often small compared to the
number of non-neoplastic cells. Therefore,
the detection of exfoliated abnormal cells by
routine cytopathology is often limited because
few atypical cells may be present in the speci-
men. There may be difficulty in separating
dysplastic cells from non-specific reactive
changes and degenerating cells or variation in
diagnostic criteria. Furthermore, exfoliated
cells are frequently contaminated with normal
cells, bacteria, and other cellular debris, which
makes molecular analysis difficult without
physical separation of the neoplastic cells.
Thus, the development of enrichment meth-
ods becomes prerequisite for the routine
detection of small numbers of exfoliated cells
and small amounts of subcellular materials in
biological fluids for molecular analysis.
Similarly, subcellular materials are in amounts
that may not be detectable by available tech-
nologies and therefore the enrichment of such
materials is of paramount importance.
Enrichment will allow exfoliated cells and
subcellular molecules, for example from urine,
to be used for genomic, proteomic, and epige-
nomic analyses that may lead to improve-
ments in the detection of bladder cancer
through measurements of alterations in
expressed genes, peptide profiles, and epige-
netic markers. 
The most common human tumors arise
from epithelial surfaces (e.g. colon, lung,
prostate, oral cavity, esophagus, stomach,
uterine cervix, bladder). Their development
often becomes apparent when tumor cells
exfoliate spontaneously into sputum, urine,
or even into various effusions. The molecular
and genetic abnormalities within these exfoli-
ated cells could be used to detect and identify
precancerous lesions or very early stage cancer
if highly sensitive technologies were clinically
available to identify the few abnormal cells
among millions of normal cells. For example,
detection of widespread microsatellite insta-
bility (MSI), as demonstrated by expansion
or deletion of repeat elements of DNA, may
be adapted for exfoliated cells in general.
With the advent of PCR-based detection of
DNA from rare neoplastic cells in body flu-
ids, mutations have been detected in ras
genes from the stools of patients with col-
orectal cancer, in p53 from the urine of
patients with bladder cancer, and in p53
genes in the sputum of patients with lung
cancer. As these assays are complex and tech-
nically challenging, they depend on the
development of novel technologies for isolat-
ing and enriching cells or subcellular materi-
als of interest. Abnormal exfoliated cells can
be routinely identiﬁed by cytologic examina-
tion of brushings and fluids, for instance,
from bronchi, pancreatic ducts, voided urine,
and effusions. Currently, fluids are usually
processed by centrifugation or membrane ﬁl-
tration. However, the detection of abnormal
exfoliated cells, for instance, cancer cells by
routine cytopathological examination may be
limited because the number of abnormal cells
may be very small compared to the number
of normal cells, is difﬁcult. Alternatively, the
cellular and nuclear changes in abnormal cells
may be minimal compared to normal cells.
This is particularly true of cytological exami-
nations of urine cytology, where many low-
grade papillary lesions are often missed. New
PCR-based technologies may substantially
enhance the sensitivity, but current technolo-
gies for isolating and analyzing exfoliated
cells are too cumbersome to be of practical
utility. The cellular and molecular changes
that ensue during tumor progression do soFellowships, Grants, & Awards
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over a number of years and in an apparently
stochastic manner. This progressive accumu-
lation of genetic and epigenetic changes in
precancerous cell populations eventually con-
fers the malignant phenotype on emerging
clonal subpopulations. In human and animal
clinical and experimental models, the pro-
gression of precancer to cancer is known to
be lengthy. For example, it takes an average
of estimated 15 to 20 years for a small adeno-
matous polyp to become malignant. Prior to
the appearance of a morphologically identi-
fied precancerous lesion, numerous genetic
and molecular alterations would have already
occurred. During histological progression
into a morphologically identiﬁable lesion, the
stochastic process of molecular events in dif-
ferent cells confers genetic heterogeneity. 
Finding molecular and genetic biomark-
ers of malignancy is particularly important in
detecting the emergence of precancerous cell
populations and is what the NCI considers to
be an “Extraordinary Opportunity.” In these
earliest stages of neoplasia, lesions should be
amenable to complete eradication. This prin-
ciple has been well-demonstrated in cervical
neoplasia, where screening for dysplastic
exfoliated cells can result in a 70% or greater
reduction in the cervical cancer mortality.
During the early stages of cancer develop-
ment, there is a window of opportunity to
detect precancerous cells with genetic or mol-
ecular biomarkers that identify and character-
ize their progression towards cancer.
Detection of genetic abnormalities in preneo-
plastic lesions poses challenges because of the
small size of lesions, the heterogeneity of pre-
cancerous cells, and their dilution by normal
cellular constituents. Therefore, assays should
be tailored to detect a small number of
abnormal cells or molecules among a large
number of normal cells or molecules in bio-
logical ﬂuids, such as in colonic washes of the
gastrointestinal tract, in sputa, and in
bronchial biopsies. 
In order to detect and analyze precancer-
ous and cancerous cells in biologic ﬂuids, there
are a variety of approaches. The most appro-
priate approach depends upon 1) the type of
biological fluid (sputum, bronchial washing,
cervical brushing, voided urine, etc.), and
2) the form of analysis to be performed (e.g.,
cytopathological analysis, morphometric
analysis, molecular biomarkers for specific
receptors or genetic changes, FISH-or-PCR
based analyses). All of these approaches require
an enrichment of atypical epithelial cells
through selective processing to concentrate the
assay target of interest. The enrichment meth-
ods currently used can be grouped into the fol-
lowing two broad categories: 1) mechanical
(centrifugation, cytospin, sucrose gradients,
etc.) and 2) antibody-based selection with
mechanical separation (FACS - flow assisted
cell sorting, MACS - magnetic assisted cell
sorting, etc.). While one type of enrichment
process can be sequentially added to another
to improve the yield, all of these methods have
good but not adequate sensitivity or speciﬁcity
required for detecting precancerous cells in
body fluids. Given that the concentration of
these cells or molecules can be very low com-
pared to other commonly present cell types or
molecules, one needs enrichment factors of 1
to 10,000 or 1 to million.
More than 80 percent of human tumors
originate from epithelial cells, often at a
mucosal surface, and are clonal in origin.
Precancerous exfoliated cells can be routinely
identiﬁed in pathology departments by cyto-
logic examination of washings or brushings
from bronchi, oral cavity, esophagus, stomach,
bile and pancreatic ducts, sputum and urine;
however, the detection of exfoliated cancer
cells by routine cytopathological examination
is limited because of the presence of few atypi-
cal cells in specimens, the difﬁculty of distin-
guishing low grade dysplasias from
non-speciﬁc reactive or inﬂammatory changes,
and the low sensitivity and specificity of the
available diagnostic methodology. These limi-
tations are particularly true of urine cytology,
where most low-grade papillary lesions are
missed on cytologic examination of urine.
New PCR-based technologies may substan-
tially enhance sensitivity, but current tech-
nologies for isolating exfoliated cells are too
cumbersome to be of practical utility. For
example, exfoliated cells are frequently conta-
minated with normal cells, bacteria, and other
cellular debris, making molecular analysis difﬁ-
cult without further physical separation of
neoplastic cells. Therefore, the development of
novel, high-throughput, sensitive technologies
for sample preparation is a prerequisite for the
successful detection of small numbers of exfo-
liated cells or small amounts of subcellular
materials, such as DNA and proteins. 
There are occasions in which the only bio-
logic materials available from patients are
stored plasma or serum samples. The amount
of DNA in these samples are generally very
low when they are obtained from normal
(healthy) individuals, but increased amounts
of circulating DNA have been found in can-
cer. The circulating DNA in plasma/serum of
cancer patients has been shown to reﬂect the
characteristics of the tumor DNA including
molecular changes, such as methylation, point
mutations, and microsatellite instability.
Fragmented nucleosomal DNA in plasma
resulting from apoptotic death of the tumor
cells may also provide an indication for tumor
DNA. There is a need to develop high-yield
technologies to isolate circulating DNA that
can be used for early detection of cancer and
the follow-up of the disease.
The primary purpose of this initiative is to
encourage the development of high-through-
put technologies to facilitate the isolation and
enrichment of exfoliated cells and subcellular
materials. In pursuit of these goals, the NCI
invites applications that address the following
areas: 1) Development of high-throughput
technologies for identifying abnormal exfoli-
ated cells and subcellular materials in body ﬂu-
ids; 2) Development of sampling technologies
for capturing and preserving exfoliated tumor
cells and subcellular materials in body ﬂuids;
3) Development of enrichment methods for
the isolation of tumor cells and subcellular
materials; 4) Development of sensitive, high-
throughput molecular, cytomorphometric,
immunologic, and other relevant technologies
to isolate tumor cells or subcellular materials
in malignant effusions to help detect low
tumor burden and distinguish reactive cells
from tumor cells.The long-term goal, to which
this initiative will eventually lead, is the devel-
opment of panels of well-characterized bio-
markers derived from exfoliated cells that can
be sampled in the clinical setting. These
methodologies will be tested and validated in
future population-based clinical trials, and
integrated into a comprehensive information
system that will be developed under the Early
Detection Research Network.
This PA will use the NIH exploratory/
developmental (R21) award mechanism. As an
applicant, you will be solely responsible for
planning, directing, and executing the pro-
posed project. The applicant may request a
project period of up to two years with a com-
bined budget for direct costs of up $275,000
for the two year period. For example, the appli-
cant may request $100,000 in the ﬁrst year and
$175,000 in the second year. The request
should be tailored to the needs of the project.
Normally, no more than $200,000 may be
requested in any single year. These grants are
non-renewable and continuation of projects
developed under this PA will be through the
traditional unsolicited investigator initiated
grant program. This PA uses just-in-time con-
cepts. It also uses the modular budgeting for-
mat. (see http://grants.nih.gov/grants/funding/
modular/modular.htm). Speciﬁcally, if you are
submitting an application with direct costs in
each year of $250,000 or less, use the modular
format. This program does not require cost
sharing as deﬁned in the current NIH Grants
Policy Statement at http://grants.nih.gov/
grants/policy/nihgps_2001/part_i_1.htm. 
Applications must be prepared using the
PHS 398 research grant application instruc-
tions and forms (rev. 5/2001). Applications
must have a Dun and Bradstreet (D&B) Data
Universal Numbering System (DUNS) num-
ber as the Universal Identiﬁer when applying
for Federal grants or cooperative agreements.
The DUNS number can be obtained by call-
ing (866) 705-5711 or through the web site at
http://www.dunandbradstreet.com/. The
DUNS number should be entered on line 11
of the face page of the PHS 398 form. The
PHS 398 document is available at
http://grants.nih.gov/grants/funding/phs398/
phs398.html in an interactive format. For
further assistance contact GrantsInfo,
301-435-0714, e-mail: GrantsInfo@nih.gov.
The title and number of the PA must be
typed on line 2 of the face page of the appli-
cation form and the YES box must be
checked.
Supplementary Instructions: All instruc-
tions for the PHS 398 (rev. 5/2001) must be
followed, with these exceptions: ResearchFellowships, Grants, & Awards
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Plan: Items a - d of the Research Plan
(Speciﬁc Aims, Background and Signiﬁcance,
Preliminary Studies, and Research Design
and Methods) may not exceed a total of 15
pages. No preliminary data is required but
may be included if it is available. Please note
that a Progress Report is not needed; compet-
ing continuation applications for an
exploratory/developmental grant will not be
accepted. Appendix: Use the instructions for
the appendix detailed in the PHS 398 except
that no more than 5 manuscripts, previously
accepted for publication, may be included. 
For the NIH Exploratory/Developmental
Grant (R21), applicants may request direct
costs in $25,000 modules, up to a total direct
cost of $275,000 for the combined two year
award period.
Applications must be received by or
mailed on or before the receipt dates
described at http://grants.nih.gov/grants/
funding/submissionschedule.htm. 
The CSR will not accept any application
in response to this PA that is essentially the
same as one currently pending initial review
unless the applicant withdraws the pending
application. The CSR will not accept any
application that is essentially the same as one
already reviewed under this PA. This does
not preclude the submission of a substantial
revision of an unfunded version of an appli-
cation already reviewed, but such application
must include an introduction addressing the
previous critique. Unfunded applications pre-
viously reviewed as investigator-initiated
applications under a different research grant
mechanism may be resubmitted as a new
application under this PA (see http://
grants.nih.gov/grants/guide/notice-
ﬁles/NOT-OD-03-019.html ). 
Contact: Mukesh Verma, Division of
Cancer Prevention, NCI, Executive Plaza
North, EPN 3144, Bethesda, MD 20892-
0001 USA, Rockville, MD 20852 (for
express/courier service), 301-496-3893, fax:
301-402-8990, e-mail: mv66j@nih.gov;
Sudhir Srivastava, Division of Cancer
Prevention, NCI, Executive Plaza North,
EPN 3142, Bethesda, MD 20892-0001
USA, Rockville, MD 20852 (for express/
courier service), 301-496-3983, fax: 301-
402-8990, e-mail: ss1a@nih.gov
Developmental Mechanisms of Human
Structural Birth Defects
The purpose of this PA is to support new,
innovative, multidisciplinary, interactive, and
synergistic program projects that integrate
basic, translational, and clinical approaches to
understanding the developmental biology
and genetic basis of congenital human mal-
formations. Each program must consist of at
least three component projects. At least one
project must be clinical or translational in
nature. The component projects must share a
common central theme, focus, or objective
on a speciﬁc developmental defect or malfor-
mation that is genotypically, mechanistically,
biologically, or phenotypically analogous or
homologous in both animal models and
humans. Any non-mammalian or mam-
malian animal model may be used, as long as
it contributes to the common overall theme
or objective of the program project. If the
component projects do not share a common
developmental gene, process, mechanism,
pathway, or phenotype, the application will
be considered nonresponsive to this. 
Annually, about four percent of all live
births in the United States involve babies with
signiﬁcant structural birth defects (more than
150,000 babies). Next to accidents, birth
defects are the leading cause of death in chil-
dren; they account for half of all pediatric
hospitalizations. In terms of the economic
costs, billions of dollars are spent over the life-
times of children born with any of 17 major,
severe, nonfatal birth defects. In sum, struc-
tural birth defects have a great impact on pub-
lic health, socioeconomics, and family life. A
high priority goal of NICHD's strategic plan
is to address the problem of human structural
birth defects. The clinical and epidemiological
aspects of human malformations were
addressed at a workshop in 1997. As a result
of that workshop, the National Institute of
Child Health and Development (NICHD),
the National Institute of Environmenal
Health Sciences (NIEHS), the National
Institute of Dental and Craniofacial Research
(NIDCR), and the U.S. Environmental
Protection Agency (U.S. EPA) issued RFA
HD-99-002, "Genetic Susceptibility and
Variability of Human Malformations." That
initiative funded several R01s and established
a basis for a network of investigators focused
on the use of molecular genetic approaches to
the study of genetic susceptibility and epi-
demiology of human malformations.
A second workshop was held in 1998
and its recommendations served as the basis
for RFA HD-99-008, "Developmental
Mechanisms of Human Malformations",
from which NICHD and NIEHS funded
several P01s. An important feature of those
P01s was the emphasis on integrating basic,
translational, and clinical research.
Combined with the R01s funded under the
first initiative, these projects expanded the
network of researchers focused on the study
of structural birth defects.
By issuing this PA, "Developmental
Mechanisms of Human Structural Birth
Defects," the NICHD plans to increase the
number of basic scientists and clinicians
involved in this network. Now that the
sequencing of the human genome is com-
plete, it is time to capitalize on the rapid
advances being made in functional genomics
and proteomics. Broadening the base of PIs
involved in this research effort will promote
the translation of these advances from the
bench to the bedside. 
The purpose of this PA is to support
new, innovative, multidisciplinary, interac-
tive and synergistic program projects that
integrate basic, translational, and clinical
approaches to understand the developmental
biology and genetic basis congenital human
malformations. Of particular interest to the
NICHD are applications proposing to study
embryonic developmental defects of general-
ized body patterning and localized anomalies
of the skeletal, nervous, and visceral systems
that lead to clinically significant congenital
structural malformations. While applications
focusing on developmental disorders that
result in mental retardation and related neu-
robehavioral disabilities are of interest to the
NICHD, they are outside the scope of this
PA. The basic science component projects
may include studies to: 1) identify and char-
acterize the genes, gene products, mutations,
polymorphisms, multigene and gene/environ-
ment interactions that play a role in normal
and abnormal embryonic patterning and
organogenesis; 2) elucidate the developmen-
tal biological processes and pathways, the
biochemical, cellular, molecular, genetic
mechanisms, and spatial and temporal gene
expression patterns which are involved in
dysmorphogenesis; and 3) examine how ter-
atogens and nutritional deficiencies disrupt
or modify gene expression and basic develop-
mental processes. 
The translational/clinical component
projects may include studies to: 1) character-
ize and classify genotypes and phenotypes of
human malformations that are comparable in
the animal models being examined; 2)
develop physical, genetic, and comparative
maps for genes involved in human malforma-
tions; 3) identify the developmental genetic
processes and molecular pathogenesis of
human malformations utilizing animal mod-
els; and 4) develop innovative molecular
genetic methods, technologies, and strategies
to enhance the diagnosis and methods for
intervention of the human malformations. 
Applicants are encouraged to incorporate
the recent scientiﬁc advances in developmen-
tal biology and genetics in their projects and
to utilize the many research resources, bioin-
formatic databases, and biotechnological
tools in their research cores. The research
cores should be structured to share work
effort and research resources (e.g., biotech-
nology, high-throughput instrumentation,
microarrays, oligonucleotide chips, animal
model development, and technical assistance)
among the research projects. The aim of the
core is to enhance the progress, productivity,
cost-effectiveness, and outcome of the
research projects. 
Applications may include new and inno-
vative approaches to investigate: 1) genetic
defects, nutritional deficiencies, teratogens
that perturb, modify, or alter gene expression
during early development; 2) the identity and
function of transcription and growth factors
in normal and abnormal gastrulation,
embryogenesis, organogenesis, and pattern-
ing, as well as their modiﬁcation by environ-
mental agents; and 3) defective embryonic
developmental processes and pathways that
ultimately lead to malformations. Fellowships, Grants, & Awards
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Research projects responsive to this PA
include, but are not limited to, the following:
1) Investigations on the identity, characteris-
tics, and mechanisms of growth factors and
growth factor receptors that function in
embryonic development and dysmorphogene-
sis of the skeletal, nervous, and visceral sys-
tems; 2) Studies of transcription factors
regulating gene expression and temporal and
spatial expression patterns during normal and
abnormal embryonic development; 3) Studies
of developmental genes, gene products, tran-
scription factors, and growth factors that
function and interact to regulate cell prolifera-
tion, cell differentiation, apoptosis, cell migra-
tion, and cell fate in embryonic development;
4) Examination of genes and molecular mech-
anisms and interactions that control normal
and abnormal body axes and symmetry dur-
ing development; 5) Studies to identify, map,
and characterize genes that play a role in sig-
nal transduction and biochemical pathways,
cell fate determination, gastrulation, embryo-
genesis, organogenesis, body patterning, and
how developmental defects, mutations, or sus-
ceptible polymorphisms lead to malforma-
tions; 6) Investigations of pharmaceutical,
nutritional, and teratogenic agents and factors
that alter genes and developmental processes
and pathways that result in dysmorphologies;
7) Investigations to characterize and classify
genotype/phenotypes of hereditary human
malformations and correlate them to
homologs in animal models; 8) Efforts to
deﬁne pleiotropic effects that genes and their
modifiers have in the spatial and temporal
development of embryonic and/or fetal
anomalies; 9) Development and validation of
new and/or improved animal models to study
the genes, mutations, mechanisms, and devel-
opmental processes and pathways that cause
human malformations; 10) Imaging and gene
expression studies to investigate and monitor
the developmental pathogenesis of dysmor-
phic features; 11) Investigations of the role of
imprinting and epigenetic factors in the devel-
opment of major congenital malformations;
12) Studies on nutritional factors (e.g., folic
acid deﬁciency) and teratogens (e.g., retinoids
and valproic acid) affecting gene/gene,
gene/receptor, gene/modifier, and gene/ter-
atogen interactions that lead to neural tube or
other structural defects; 13) Examination of
the role and developmental biology of neural
crest cells in normal embryonic development
and how defects in cell proliferation, differen-
tiation, migration, and patterning may result
in major structural birth defects;
14) Elucidation of the underlying genetic and
molecular mechanisms that alter normal
developmental processes in drug-induced
(e.g., Accutane, Thalidomide) malformations;
15) Identification and characterization of
polymorphisms/mutations of metabolic genes
that function in the development of structural
birth defects. The topics listed above are only
examples, are not in priority order, and are
not intended to be all-inclusive. Investigators
are encouraged to explore and develop new,
innovative projects and research cores that
are consistent with the overall objectives of
this PA.
Applicants are encouraged to incorporate
the recent scientiﬁc advances in developmen-
tal biology and genetics in their projects and
to utilize the many research resources, bioin-
formatic databases, and biotechnological
tools in their research cores. The research
cores should be structured to share work
effort and research resources (e.g., biotech-
nology, high-throughput instrumentation,
microarrays, oligonucleotide chips, animal
model development, and technical assistance)
among the research projects. The aim of the
cores is to enhance the progress, productivity,
cost-effectiveness, and outcome of the
research projects.
This PA will use the NIH Program
Project Grant (P01) award mechanism. The
P01 supports broadly based multidisciplinary
research programs that have a well-defined
central research focus or objective. An impor-
tant feature is that the interrelationships
among the individual projects will result in a
greater contribution to the overall program
goals than if each project were pursued inde-
pendently. The P01 grant requires a mini-
mum of three interrelated individual research
projects that contribute to the overall pro-
gram objective. At least one component pro-
ject must be translational or clinical in
nature. The application may request support
for certain common core resources. As an
applicant you will be solely responsible for
planning, directing, and executing the pro-
posed project. Guidelines for the NICHD
Program Project (P01) Grant may be found
at http://www.nichd.nih.gov/funding/
dsr_p01_guide.htm. 
The Program Director for the overall
grant and the principal investigator for each
component project should plan to attend an
annual NIH-sponsored two-day meeting in
Bethesda, MD. In addition, this meeting will
be attended by investigators supported
through the two previous RFAs (HD-99-
002, Genetic Susceptibility & Variability of
Human Malformations, and HD-99-008,
Developmental Mechanisms of Human
Malformations). The meeting will provide an
opportunity for all the investigators to com-
municate, discuss the progress of their
research, exchange ideas and information,
share resources, and foster collaborations that
are relevant to the research goals of the
NICHD birth defects initiative. This require-
ment is designed to establish an interactive
network of investigators who are interested in
multidisciplinary approaches to enhancing
our understanding of the epidemiology, etiol-
ogy, pathogenesis, and developmental biol-
ogy and genetics of structural birth defects.
All applications should include a request
for funds to support attendance of the
Program Director and project principal inves-
tigators at the annual meetings, as well as a
statement of agreement to participate in these
meetings and to cooperate with investigators
at other program project sites. A data-sharing
plan must be included as outlined in the
recent NIH Guide notice http://
grants.nih.gov/grants/guide/notice-
ﬁles/NOT-OD-03-032.html.
Applications must be prepared using the
PHS 398 research grant application instruc-
tions and forms (rev. 5/2001). Applications
must have a Dun and Bradstreet (D&B)
Data Universal Numbering System (DUNS)
number as the Universal Identifier when
applying for Federal grants or cooperative
agreements. The DUNS number can be
obtained by calling (866) 705-5711 or
through the web site at http://www.dunand-
bradstreet.com/. The DUNS number should
be entered on line 11 of the face page of the
PHS 398 form. The PHS 398 is available at
http://grants.nih.gov/grants/funding/phs398/
phs398.html in an interactive format. For
further assistance contact GrantsInfo, 301-
435-0714, e-mail: GrantsInfo@nih.gov.
The title and number of this PA must be
typed on line 2 of the face page of the appli-
cation form and the YES box must be
checked.
Applications submitted in response to
this PA will be accepted at the standard
application deadlines, which are available at
http://grants.nih.gov/grants/dates.htm.
Application deadlines are also indicated in
the PHS 398 application kit.
Applications must be mailed on or before
the receipt dates described at http://
grants.nih.gov/grants/funding/submission-
schedule.htm. 
The CSR will not accept any application
in response to this PA that is essentially the
same as one currently pending initial review
unless the applicant withdraws the pending
application. The CSR will not accept any
application that is essentially the same as one
already reviewed. This does not preclude the
submission of a substantial revision of an
application already reviewed, but such appli-
cation must include an Introduction address-
ing the previous critique.
Contact: Lorette Javois, Developmental
Biology, Genetics and Teratology Branch,
Center for Developmental Biology and
Perinatal Medicine, NICHD, 6100
Executive Blvd, 4B01 MSC 7510, Bethesda,
MD 20892-7510 USA, 301- 496-5541, fax:
301-480-0303, e-mail: javoisl@mail.nih.gov